Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
A new clinical trial for breast cancer, published in The Lancet, shows that a single fraction of targeted intraoperative radiotherapy (TARGIT) delivered with the ZEISS INTRABEAM® at time of lumpectomy is non-inferior to traditional external beam radiation (EBRT) delivered over three to six weeks after breast conserving surgery, for a select group of patients.
"The most important benefit of TARGIT for a woman with breast cancer is that it allows her to complete her entire local treatment at the time of her operation, with lower toxicity to the breast, the heart and other organs. Our research supports the use of TARGIT concurrent with lumpectomy, provided patients are selected carefully, and should allow patients and their clinicians to make a more informed choice about individualizing their treatment, saving time, money, breasts, and lives," according to Professor Jayant S. Vaidya, FRCS MD, PhD from the international TARGIT investigators group, in the accompanying press release on the Lancet publication of the research study.
Since 1998, the international TARGIT research group has investigated whether radiotherapy targeted to the tumour bed at the time of surgery can reduce the risk of recurrence in early breast cancer as effectively as the traditional three to six week EBRT.
Traditionally, whole-breast EBRT is given after lumpectomy (breast conserving surgery) to reduce the risk of recurrence of cancer in the breast and of breast cancer mortality. EBRT typically is given over a course of three to six weeks requiring patients to receive treatment at radiotherapy centers for 20-30 days. In some cases, women suitable for breast conserving surgery, but living far from a radiotherapy center and unable to attend daily post-surgical treatments may even undergo mastectomy as an alternate.
In the TARGIT approach, during surgery after removal of the tumor, the affected tissue in the tumor bed is irradiated from within the breast using the ZEISS INTRABEAM. The TARGIT study results show that targeted intraoperative radiotherapy delivered with ZEISS INTRABEAM can reduce the risk of recurrence of the cancer as effectively as a traditional 3- to 6-week course of whole breast irradiation in selected women with invasive ductal carcinoma.
The TARGIT-A trial has been to date the largest multicenter randomized clinical trial for intraoperative radiotherapy (IORT) in the field of partial breast irradiation, with 3451 patients in 33 international centers from Europe, the United States, and Australia. The TARGIT-A trial followed an individualized risk-adapted approach, meaning, that patients who had received TARGIT at the time of surgery showed in the final pathology additional unforeseen risk factors, received supplemental EBRT, which occurred for about 15% of the patients. The 5-year results for local recurrence and the first analysis of overall survival of the TARGIT-A trial have now been reported. Comparing TARGIT with EBRT the difference in 5-year local recurrence between the two treatments was less than 2.5% and therefore considered "non-inferior" to standard EBRT (daily doses for 3-6 weeks) in treating the cancer. Overall mortality was 3.9% with TARGIT and 5.3% with EBRT, due to fewer deaths from cardiovascular causes and other cancers.
Based on statistical comparison of breast cancer recurrence, number of deaths and side effects of TARGIT versus EBRT the authors conclude: "TARGIT concurrent with lumpectomy within a risk-adapted approach should be considered as an option for eligible patients with breast cancer carefully selected as per the TARGIT-A trial protocol."
"We commend the international TARGIT group pioneered by Professor Jayant Vaidya and Professor Michael Baum for this outstanding research on this new treatment option that can benefit many breast cancer patients. The TARGIT group's research will further enhance adoption by radiation oncologists and breast surgeons worldwide and will broaden the application of our ZEISS INTRABEAM for this new option in the fight against cancer," says Dr. Ludwin Monz President and CEO of Carl Zeiss Meditec AG.
Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial, Prof Jayant S Vaidya PhD, Prof Frederik Wenz MD, Prof Max Bulsara PhD, Prof Jeffrey S Tobias FRCR, Prof David J Joseph FRACR, Prof Mohammed Keshtgar PhD, Henrik L Flyger MD, Samuele Massarut MD, Michael Alvarado MD, Prof Christobel Saunders FRACS, Prof Wolfgang Eiermann MD, Marinos Metaxas PhD, Elena Sperk MD, Prof Marc Sütterlin MD, Douglas Brown FRCS, Prof Laura Esserman MD, Mario Roncadin MD, Prof Alastair Thompson FRCS, Prof John A Dewar FRCR, Helle M R Holtveg MD, Steffi Pigorsch MD, Mary Falzon FRCPath, Eleanor Harris MD, April Matthews BS, Chris Brew-Graves MS, Ingrid Potyka PhD, Tammy Corica BSc, Norman R Williams PhD, Prof Michael Baum MD, The Lancet, Early Online Publication, 11 November 2013 doi:10.1016/S0140-6736(13)61950-9
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Breast Cancer category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Carl Zeiss Meditec AG. "New breast cancer study: Results of the TARGIT-A clinical trial." Medical News Today. MediLexicon, Intl., 3 Dec. 2013. Web.
17 Apr. 2014. <http://www.medicalnewstoday.com/releases/269575>
Carl Zeiss Meditec AG. (2013, December 3). "New breast cancer study: Results of the TARGIT-A clinical trial." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/269575.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2014 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.